# TB-500 Tissue Repair Research: Wound Healing, Re-Epithelialization, and Collagen Remodeling | TB-500 > TB-500 tissue repair research, drawn from the thymosin beta-4 wound-healing record: +42% / +61% re-epithelialization in rats, corneal healing, burn and venous-ulcer findings, and 2025 diabetic-ulcer work — cited and identity-flagged. The wound-healing record that underwrites the tissue-repair interest in TB-500 — drawn almost entirely from full-length thymosin beta-4, flagged as such, and dimensioned to its studies. ## TB-500 tissue repair: the wound-healing record TB-500 tissue repair research is, in practice, the thymosin beta-4 wound-healing record read through the actin-binding fragment. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction by at least 11% by day seven, and increased collagen deposition and angiogenesis [3]. The migration signal is potent at trace amounts. In the same line of work, as little as 10 pg of thymosin beta-4 stimulated keratinocyte migration two- to three-fold [3]. That is a parent-protein finding measured in an animal and in cell assays, not a demonstration that the seven-mer reproduces it in people. The identity caveat applies throughout this page. Where a finding used full-length thymosin beta-4 rather than the Ac-LKKTETQ fragment — which is nearly everywhere in the repair literature — it is parent-protein evidence. The corpus flags it; so does this digest. ## What TB-500 (Thymosin Beta-4) Has Been Studied For What TB-500, by way of thymosin beta-4, has been studied for spans several injured tissues. In a murine corneal model, thymosin beta-4 promoted corneal wound healing and decreased inflammation after alkali injury [12]. In a diabetic (db/db) burn-wound model, it improved healing via downregulation of the receptor for advanced glycation end-products [13]. A European prospective study reported wound-healing benefit in venous ulcers — early human evidence, with the topical full-length protein [14]. Recent work extends the angle. A 2025 comparative study found that combined thymosin beta-4 and selenium improved diabetic-ulcer healing in a metabolically impaired model [15]. Also in 2025, an engineered tandem thymosin peptide promoted corneal wound healing — a next-generation thymosin-derived construct designed for greater repair potency, part of the clinical-grade topical thymosin beta-4 (RGN-259) ophthalmic line [16]. Read honestly, this is a benefits section only in the literal sense: it lists what was measured, in which model, at what scale. None of it is human proof for the seven-residue fragment [1]. For the connective-tissue and muscle questions, see the [TB-500 side effects](/faq) and recovery answers on the FAQ. #### How long does it take for TB-500 to work for injury healing? No validated human healing timeline exists. In a rat full-thickness wound model, thymosin beta-4 raised re-epithelialization by about 42% at four days and up to about 61% at seven days versus saline [3] — an animal timescale, not a human dosing schedule. #### Does TB-500 help wound healing? In animal and topical models, thymosin beta-4 accelerated re-epithelialization, increased wound contraction, collagen deposition, and angiogenesis, and as little as 10 pg stimulated keratinocyte migration [3]; it also improved burn-wound [13] and venous-ulcer healing [14], and 2025 work pairs it with selenium for diabetic ulcers [15]. These are full-length-thymosin-beta-4 and topical findings, not proof of the seven-mer in humans [1]. ## Corneal, oral, and route questions Corneal repair is one of the better-controlled corners of the record. Alongside the alkali-injury murine work [12], the 2025 engineered tandem thymosin peptide improved corneal wound healing within the topical thymosin beta-4 ophthalmic line [16]. These ophthalmic findings are topical, on the parent protein or engineered constructs — not the systemic seven-mer. The route question matters for anyone reading the literature carefully. The repair studies use topical, intraperitoneal, and intravenous administration. As a peptide, TB-500 is not studied as an oral therapy, and oral bioavailability is not established [1]. #### Does TB-500 help corneal or eye healing? Thymosin beta-4 promoted corneal wound healing and reduced inflammation after alkali injury in mice [12], and a 2025 engineered tandem thymosin peptide improved corneal wound healing — part of the clinical-grade topical thymosin beta-4 (RGN-259) ophthalmic line [16]. Corneal data are among the better-controlled thymosin beta-4 repair findings. #### Can TB-500 be taken orally? The repair literature uses topical, intraperitoneal, and intravenous routes; as a peptide, TB-500 is not studied as an oral therapy and oral bioavailability is not established [1]. There is no controlled human oral dosing evidence [1]. ## Collagen remodeling, scar reduction, and why the part-vs-whole line matters The remodeling story runs through the cytoskeleton. Because thymosin beta-4 controls actin dynamics and cell migration, the proteins it influences during repair extend to collagen deposition and matrix turnover: in the rat full-thickness wound model, treated wounds showed increased collagen deposition alongside the accelerated re-epithelialization and angiogenesis [3]. A consolidated review attributes part of the anti-scarring effect to a decrease in myofibroblast number — the contractile cells that drive fibrosis — which is how the same molecule can speed closure while reducing scar [10]. This is the point where the fragment-versus-protein line stops being pedantic and starts being decision-relevant. Almost every remodeling finding above was measured with full-length thymosin beta-4 of about 4963 Da, not the roughly 889 Da Ac-LKKTETQ seven-mer sold as TB-500 [1]. The motif TB-500 carries is the actin-binding core, so a mechanistic bridge is plausible — but plausibility is not the same as a controlled demonstration, and there are no completed human trials of the fragment for wound repair [1]. The 2026 Sports Medicine review draws the practical conclusion bluntly: many unapproved peptides, TB-500 among them, show favorable tissue-repair outcomes in animal models, but rigorous human safety data are scarce and the compounds operate largely outside regulatory oversight [17]. That is the honest frame for the whole tissue-repair record — strong animal and parent-protein signal, thin human and fragment-specific proof. --- The TB-500 literature drawn to spec on a single drawing sheet — the Ac-LKKTETQ fragment dimensioned out from its thymosin beta-4 parent, the empty human-trial cell left in the title block, and the FDA 503A standing stamped before anything else; no clinic drafted it and nothing here is dispensed or sold.